Cover Image
市場調查報告書

肺部藥物輸送系統:技術和全球市場

Pulmonary Drug Delivery Systems: Technologies and Global Markets

出版商 BCC Research 商品編碼 224407
出版日期 內容資訊 英文 214 Pages
訂單完成後即時交付
價格
Back to Top
肺部藥物輸送系統:技術和全球市場 Pulmonary Drug Delivery Systems: Technologies and Global Markets
出版日期: 2014年05月23日 內容資訊: 英文 214 Pages
簡介

全球肺部藥物輸送技術的市場,2013年達到324億美元的規模,此後以年複合成長率(CAGR)6.2%擴大,預計2018年達439億美元的規模。

本報告提供肺部藥物輸送系統的技術與市場相關調查分析、目前所利用的技術及產品種類與概要、新登場的肺部藥物輸送技術趨勢、產品與技術開發趨勢、吸入用藥物、全球及美國的肺部藥物輸送技術市場變化、法律規章的修改和對市場的影響,再加上主要企業簡介,以及彙整專利趨勢等資料,為您概述為以下內容。

第1章 簡介

第2章 摘要

第3章 概要

  • 技術趨勢
  • 肺部藥物輸送

第4章 肺部藥物輸送系統

  • 肺部藥物輸送系統的優點

第5章 肺部藥物輸送系統:利用的藥物

  • 目前所利用的吸入藥物和市場

第6章 全球肺部藥物輸送技術市場

  • 全球呼吸系統市場

第7章 世界市場趨勢

  • 法律規章的修改:肺部藥物輸送的障礙

第8章 主要企業

第9章 開發、聯盟

  • 現在及未來的開發趨勢、預測
  • 臨床開發中的產品

第10章 專利分析

  • 專利環境

第11章 索引

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: HLC094B

The global market for pulmonary drug delivery technologies reached $32.4 billion in 2013 and is expected to grow to $43.9 billion in 2018, with a compound annual growth rate (CAGR) of 6.2%.

This report provides:

  • A detailed overview and thorough analysis of the present and future global markets for pulmonary drug delivery technologies
  • Analyses of global market trends, with data from 2012 and 2013, and projections of compound annual growth rates (CAGRs) through 2018.
  • Identification of emerging pulmonary drug delivery technologies, particularly with regard to inhaled drug delivery systems
  • Information on technological developments, product innovations, and recent strategic industry activities of major players across different product categories
  • Examination of devices currently being used for drug delivery to the lungs, new developments, spending trends, and revenue prospects for these technologies
  • Comprehensive profiles of leading companies in the industry.

REPORT SCOPE

INTRODUCTION

STUDY GOALS AND OBJECTIVES

This BCC Research market research report, Pulmonary Drug Delivery Systems: Technologies and Global Markets, provides a detailed overview and detailed analysis of the present and future global market for pulmonary drug delivery technologies.

This report analyzes in detail the pulmonary drug delivery technologies currently in use and that are available. This report includes products in this market and detailed analyses of the markets and competitive environments. It also analyzes current and future market prospects.

The report provides a comprehensive review of emerging pulmonary drug delivery technologies, particularly with regard to inhaled drug delivery systems. The analysis reviews technological developments, product innovations and recent strategic industry activities of major players across different product categories. It reviews their strengths and weaknesses, opportunities and the threats facing various devices and drugs in this market space.

The report also reviews developments already on the market, major issues involved in the research and development (R&D) of more effective drug/devices for drug delivery to the lungs and new products in development.

REASONS FOR DOING THE STUDY

Pulmonary drug delivery originated as a more relevant alternative for delivering drugs to the lungs. Respiratory conditions such as asthma, chronic obstructive pulmonary (COPD) and emphysema are therapeutic areas of the pulmonary space. Recent technological advancements have applied the application of pulmonary devices to the treatment of nonrespiratory conditions also such as diabetes and migraines.

The recent trends and research in the formulating sector have grown tremendously and increased sales of dry powder inhalers (DPIs), and slowly replaced metered-dose inhalers (MDIs).

Pulmonary delivery of drugs for the treatment of respiratory diseases gives a faster, simpler and easier therapeutic effect compared to systemic treatments for these indications. In addition, it also reduces side effects associated with many drugs. Still, understanding the trends in this market, and currently available drug/device combinations and improving them and eliminating risks and problems, will help in faster, effective drug delivery to the lungs.

SCOPE AND FORMAT

The report reviews global markets for pulmonary drug delivery technologies and new developments, and forecasts trends for use of current drug/devices systems for pulmonary drug delivery and safety and toxicology through 2018. The report presents important drug/device and technologies, latest developments, market share by drug/device and drug and disease type, current products on the market, market share by company or product, and statistical information for types of respiratory diseases prevalent worldwide, with special emphasis on the U.S. market.

The report also includes current issues and trends affecting the industry including costs, and factors influencing demand will be discussed. The report covers products in development, new technologies, trends, alliances, patents and mergers. The report offers market data with respect to segments and geography. It also provides market trends with respect to drivers, restraints and opportunities.

INTENDED AUDIENCE

This report is an exhaustive study of the worldwide pulmonary drug delivery device market, giving crucial statistics and analysis on existing technologies, the latest trends, market structure, market size, key drug segments, important trends in technology development, influencers, major opportunities, and market shares of key players and inhaled drug/device and drug. This report may prove crucial for drug development companies in the pulmonary drug delivery space, such as potential investors in the concerned sector. This report discusses drug/device currently being used for pulmonary drug delivery to the lungs, new developments surrounding these systems, current spending trends and revenue prospects for these technologies. The report provides relevant market data for 2011 to 2018 and also covers commercial prospects for pulmonary devices and current inhalers in use and their future.

METHODOLOGY

Both primary and secondary research methodologies were used in preparing this report. Secondary sources include books, newspapers, trade journals, white papers, industry portals, interviews, government agencies, trade associations, industry news, and developments and access to paid databases. The base year of the report is 2013, with forecast data provided through 2018. Historical, base year and forecast data are provided for each market segment of this report. The report provides a comprehensive review of emerging pulmonary drug delivery technologies, particularly with regard to inhaled drug delivery systems (both drug and device combined). The analysis reviews new technological developments, product innovations/introductions and recent strategic industry activities of major players across various product categories. Growth rates are determined through a compilation of data, including past trends, future trends, demographics, incidence, mortality, products in R&D and current product growth.

ANALYST'S CREDENTIALS

Usha Nagavarapu is an experienced pharmaceutical professional with scientific and alliance development experience. She has more than 10 years of drug and device product development and alliance management experience. She has managed preclinical discovery programs from target identification through design of Phase I testing, including Investigational New Drug (IND)-enabling studies, and assisted out-licensing and portfolio development activities. Strong focus areas include oncology, dermatology, and cardiovascular diseases. She also has extensive experience working with early startups to fulfill operational obligations while minimizing overall operational cost and burdens.

Table of Contents

CHAPTER 1 INTRODUCTION

  • STUDY GOALS AND OBJECTIVES
  • REASONS FOR DOING THE STUDY
  • SCOPE AND FORMAT
  • INTENDED AUDIENCE
  • METHODOLOGY
  • RELATED BCC RESEARCH REPORTS
  • ANALYST'S CREDENTIALS
  • BCC RESEARCH WEBSITE
  • DISCLAIMER

CHAPTER 2 SUMMARY

  • SUMMARY TABLE GLOBAL MARKET FOR PULMONARY DRUG DELIVERY TECHNOLOGIES, THROUGH 2018 ($ MILLIONS)
  • SUMMARY FIGURE GLOBAL MARKET FOR PULMONARY DRUG DELIVERY TECHNOLOGIES, 2011-2018 ($ MILLIONS)

CHAPTER 3 OVERVIEW

  • CURRENT MARKET TRENDS
    • TECHNOLOGY
    • TABLE 1 COMMONLY USED INHALED DRUGS
    • DRUG DELIVERY IN THE MODERN WORLD
    • INHALATION AS A TECHNIQUE 1
  • PULMONARY DRUG DELIVERY
  • TABLE 2 KEY FACTS
    • CONTRAINDICATIONS
    • TABLE 3 ADVANTAGES AND DISADVANTAGES OF MDIS
    • TABLE 4 ALTERNATIVE TO CFC MDIS
    • TABLE 5 MDIS PHASE-OUT DATES: UNITED STATES
    • DRY POWDER INHALERS
    • TABLE 6 COMMON DPI DEVICES
    • TABLE 7 DPI: ADVANTAGES AND DISADVANTAGES
      • Twisthaler
    • ACCESSORY DEVICES
    • NEBULIZERS
    • TABLE 8 ADVANTAGES AND DISADVANTAGES OF NEBULIZERS
    • PULMONARY CONDITIONS AND THERAPIES
    • RESPIRATORY SYSTEM
      • Lung
      • Role of Particle Size
    • SYSTEMIC AND LOCAL THERAPY
    • PULMONARY DRUG DELIVERY DEVICES
      • Device Characteristics
    • PULMONARY DRUG DELIVERY-THE FUTURE
    • INHALER DEVICES
    • TABLE 9 INHALER DEVICES AND CHARACTERISTICS
    • TABLE 10 DOSAGE FORMS-INHALERS
      • Available Products
      • TABLE 11 METERED DOSE INHALERS
      • TABLE 12 DRY POWDER INHALERS
    • COMMONLY USED INHALERS
    • TABLE 13 COMMON COPD INHALERS
    • INHALER-DRUG PROFILES
      • Aerosol Aztreonam (Cayston)
      • Dulera (Mometasone Furoate/Formoterol Fumarate Dihydrate)
      • Amikacin
      • Phase III INHALE Study Program
    • SYSTEMIC PULMONARY DELIVERY
      • Development of Exubera
      • Aerogen and Dance Pharmaceuticals
      • Safety Concerns
      • Future
      • Insulin-Exubera
      • MannKind's-Afrezza
      • Clinical Results
        • Study 171
        • Summary
        • Key Players
        • Pulmonary Drug Delivery-In a New Light
    • ASTHMA AND COPD-MAJOR RESPIRATORY DISEASE CONDITIONS
      • Asthma: Primary Respiratory Syndrome
        • Asthma and Obesity
        • TABLE 14 ASTHMA AND BIOMARKERS
        • Monitoring of Asthma
        • TABLE 15 INHALED STEROIDS (ASTHMA INHALERS)
        • TABLE 16 SYSTEMIC STEROIDS FOR ASTHMA TREATMENT
      • Delivery Methods
      • Chronic Obstructive Pulmonary Disease (COPD)
        • What is COPD?
        • COPD and Causative Factors
        • TABLE 17 COPD AND LUNG DAMAGE
      • Diagnosis of COPD
      • COPD and Treatment
    • METHODS OF DRUG DELIVERY
    • TABLE 18 COMMON COPD INHALERS ON THE MARKET
      • Aerosols
      • TABLE 19 COPD DRUGS ON THE MARKET
      • Formulations
    • INHALATION MARKET
      • Asthma Prevalence and Statistics
      • COPD and Incidence
      • Disease and Epidemiology
      • TABLE 20 INHALED DRUGS AND MARKET OPPORTUNITIES: CURRENT MARKET FOR INHALED DRUGS, 2010 (% MARKET SHARE)

CHAPTER 4 PULMONARY DRUG DELIVERY SYSTEM

  • BENEFITS OF PULMONARY DRUG DELIVERY SYSTEMS
    • INHALER DEVICES
    • TABLE 21 INHALER DEVICES
    • PULMONARY DRUG DELIVERY TECHNOLOGIES
      • Technology Descriptions
      • Wide Array of Applications
      • TABLE 22 DRUGS AND THERAPEUTIC AGENTS ADMINISTERED BY INHALATION
    • INHALERS
      • Metered-dose Inhalers
      • MDIs-How Does It Work?
      • History
        • MDIs and Drug Delivery
      • Advantages and Challenges for MDIs
      • MDIs and Corticosteroids
      • TABLE 23 BRAND NAME METERED DOSE INHALERS (CORTICOSTEROIDS)
        • Bronchodilators
        • TABLE 24 BRAND NAME METERED DOSE INHALERS (BRONCHODILATORS)
        • Combination Inhalers
        • Nonsteroidal Inhalers
        • Problems with MDI Use and Spacers 6
        • Propellants and MDI Development 6
      • Montreal Protocol
      • Millions Use Inhalers for Asthma or COPD
      • TABLE 25 LIST OF INHALERS FOR ASTHMA AND COPD WITHOUT CFCS
      • TABLE 26 LIST OF METERED DOSE INHALERS AND INGREDIENTS
      • Fluticascone
      • Fluticasone and Salmeterol
      • Flunisolide
      • Beclomethasone
    • TRANSITION TO HFA PROPELLANTS
      • Chlorofluorocarbons (CFCs)
      • TABLE 27 THE SEVEN CFC INHALERS
      • Analgesic Inhalers
    • DRY POWDER INHALER (DPI)
    • TABLE 28 TYPES OF DPI DEVICES
      • Types of DPI Devices
      • TABLE 29 DPIS CURRENTLY ON THE MARKET
      • TABLE 30 TYPES OF DRY POWDER INHALERS (DPI)
        • DPIs for Children
      • Nebulizers
        • How Do They Work?
        • Use
        • TABLE 31 Nebulizers and Drugs
        • TABLE 32 NEBULIZERS: ADVANTAGES AND DISADVANTAGES
        • Ultrasonic Nebulizers
        • TABLE 33 VIBRATING MESH NEBULIZERS
        • Small Volume Nebulizers: Electronic Vibrating Mesh (VM) Nebulizer
      • Factors Influencing Clinical Effectiveness of Inhalation Devices
    • CONCLUSIONS 8

CHAPTER 5 PULMONARY DRUG DELIVERY: DRUGS IN USE

  • CURRENT INHALATION DRUGS AND MARKET
    • AEROSOL AZTREONAM (CAYSTON)
    • DULERA (MOMETASONE FUROATE/FORMOTEROL FUMARATE DIHYDRATE)
    • PULMONARY DELIVERY OF SYSTEMIC DRUGS
      • Antibiotics
      • Analgesics
      • Anti-emetics
      • TABLE 34 THERAPEUTIC AGENTS ADMINISTERED BY INHALATION
      • Pulmonary Specific Vasodilators
        • Nicotine
      • Nebulizers for Pediatric Care
        • Vaccines
      • Obesity
      • Drugs and Inhalers: How Do They Work?
      • TABLE 35 SHORT-ACTING BRONCHODILATOR INHALERS
      • TABLE 36 LONG-ACTING BRONCHODILATOR INHALERS
        • Steroid Inhalers
        • TABLE 37 INHALED STEROID MEDICATIONS
        • TABLE 38 COMBINATION INHALERS
      • Breath-Activated Inhalers
      • Nebulizers
      • Pulmonary Delivery
      • Controlled Release
      • Formulations
        • Lactose Carrier Systems
        • Liposomes
        • PulmoSpheres
      • Biodegradable Polymers

CHAPTER 6 GLOBAL MARKET FOR PULMONARY DRUG DELIVERY TECHNOLOGIES

  • RESPIRATORY DISEASES
    • ASTHMA AND CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MARKET 102
    • TABLE 39 ASTHMA AND CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MARKET AND FORECAST, 2013 AND 2018 ($ MILLIONS)
    • FIGURE 1 ASTHMA AND CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MARKET AND FORECAST, 2013 AND 2018 ($ MILLIONS)
    • GLOBAL RESPIRATORY DEVICES MARKET
      • COPD
    • DRUG DELIVERY MARKET
      • Drug Delivery Technologies and Market
      • European Drug Delivery Market
    • GLOBAL PHARMACEUTICAL MARKET 106
    • TABLE 40 GLOBAL PHARMACEUTICAL SALES AND FORECAST, THROUGH 2018 ($ BILLIONS)
    • FIGURE 2 GLOBAL PHARMACEUTICAL SALES AND FORECAST, 2011-2018 ($ BILLIONS)
      • Pharmaceutical Growth Rates
      • Emerging Markets
      • TABLE 41 TOTAL UNAUDITED AND AUDITED GLOBAL PHARMACEUTICAL MARKET BY REGION, THROUGH 2017 ($ BILLIONS)
      • A Shift to Generics as Patents Expire
      • Growth in New Drugs
      • United States Pharmaceutical Industry
      • Top 20 Pharmaceutical Companies
      • TABLE 42 TOP 20 PHARMACEUTICAL COMPANIES, 2012 ($ MILLIONS)
      • TABLE 43 TWELVE LARGEST PHARMACEUTICAL COMPANIES, 2010 ($ MILLIONS)
    • DRUG DELIVERY
    • DRUG DELIVERY MARKET
      • Global Market
      • TABLE 44 KEY PLAYERS: DRUG DELIVERY TECHNOLOGIES MARKET
      • TABLE 45 TOTAL GLOBAL DRUG DELIVERY TECHNOLOGIES MARKET, THROUGH 2018 ($ MILLIONS)
      • FIGURE 3 TOTAL GLOBAL DRUG DELIVERY TECHNOLOGIES MARKET, 2011-2018 ($ MILLIONS)
      • TABLE 46 GLOBAL DRUG DELIVERY TECHNOLOGIES MARKET, THROUGH 2018 ($ MILLIONS)
      • FIGURE 4 GLOBAL DRUG DELIVERY TECHNOLOGIES MARKET, 2011-2018 ($ MILLIONS)
      • Oral Drug Delivery
      • TABLE 47 GLOBAL ORAL DRUG DELIVERY TECHNOLOGIES MARKET, THROUGH 2018 ($ MILLIONS)
      • FIGURE 5 GLOBAL ORAL DRUG DELIVERY TECHNOLOGIES MARKET, 2012-2018 ($ MILLIONS)
      • Implantable and Injectable Drug Delivery
      • TABLE 48 GLOBAL IMPLANTABLE/INJECTABLE DRUG DELIVERY MARKET, THROUGH 2018 ($ MILLIONS)
      • FIGURE 6 GLOBAL IMPLANTABLE/INJECTABLE DRUG DELIVERY MARKET, 2011-2018 ($ MILLIONS)
      • Transdermal Drug Delivery
      • TABLE 49 GLOBAL TRANSDERMAL DRUG DELIVERY TECHNOLOGIES MARKET, THROUGH 2018 ($ MILLIONS)
      • FIGURE 7 GLOBAL TRANSDERMAL DRUG DELIVERY TECHNOLOGIES MARKET, 2011-2018 ($ MILLIONS)
      • Drug Delivery Market in the U.S. 120
      • TABLE 50 U.S. DRUG DELIVERY TECHNOLOGIES MARKET AND FORECAST, THROUGH 2018 ($ MILLIONS)
      • FIGURE 8 U.S. DRUG DELIVERY TECHNOLOGIES MARKET, 2011-2018 ($ MILLIONS)
  • PULMONARY DRUG DELIVERY
  • TABLE 51 TOP ASTHMA AND COPD DRUGS
  • TABLE 52 GLOBAL PULMONARY DELIVERY TECHNOLOGIES MARKET, THROUGH 2018 ($ MILLIONS)
  • FIGURE 9 GLOBAL PULMONARY DELIVERY TECHNOLOGIES MARKET, 2011-2018 ($ MILLIONS)
  • TABLE 53 LEADING PULMONARY DRUG DELIVERY PLAYERS
  • TABLE 54 PULMONARY DELIVERY TECHNOLOGIES MARKET IN THE U.S. AND EUROPE, THROUGH 2018 ($ MILLIONS)
  • FIGURE 10 PULMONARY DRUG DELIVERY TECHNOLOGIES MARKET IN THE U.S. AND EUROPE, 2011-2018 ($ MILLIONS)
    • ASTHMA AND COPD MARKET
    • TABLE 55 WORLDWIDE MARKET FOR TOP INHALED DRUGS: SALES AND FORECAST 2012-2013 ($ MILLIONS)
    • TABLE 56 UNITED STATES: TOP ASTHMA DRUGS SALES, 2012 AND 2013 ($ MILLIONS)
    • WHY PULMONARY DRUG DELIVERY?
      • Metered Dose Inhalers (MDIs)
      • TABLE 57 MARKET FOR MDI TECHNOLOGIES, THROUGH 2018 ($ MILLIONS)
      • FIGURE 11 MARKET FOR MDI TECHNOLOGIES, 2011-2018 ($ MILLIONS)
    • DRY POWDER INHALATION (DPI)
    • TABLE 58 DPI DEVICES
    • TABLE 59 MARKET FOR DPI TECHNOLOGIES, THROUGH 2018 ($ MILLIONS)
    • FIGURE 12 MARKET FOR DPI TECHNOLOGIES, 2011-2018 ($ MILLIONS)
      • Inhalers: Global Cost Comparison
    • GENERICS
      • Phase-out of CFC Inhalers and Historical Perspectives
    • CURRENT MARKET DYNAMICS
      • Rescue Inhalers
      • TABLE 60 TYPES OF INHALER UNITS SOLD WORLDWIDE, 2007 (%)
      • Combination Inhalers
      • TABLE 61 UNITED STATES: TOP ASTHMA DRUGS PRESCRIPTIONS, 2012 ($ MILLIONS)
      • Product Descriptions
        • Symbicort
        • ProAir and Qvar
        • Dulera
        • Spiriva
        • Advair
      • New Products
        • Breo Ellipta
        • Anoro Ellipta
        • Other Respiratory Development Programs
        • TABLE 62 NEW PRODUCTS IN THE RESPIRATORY DRUG MARKET, 2013
        • Ultibro Breezhaler
      • Impact on Advair Market in United States and Healthcare Changes
      • TABLE 63 ADVAIR SALES AND FORECAST, 2011-2015 ($ MILLIONS)
      • TABLE 64 GLAXOSMITHEKLINE: RESPIRATORY DRUGS PHARMACEUTICALS-THREE MONTHS ENDED JUNE 30, 2013 ($ MILLIONS)
        • Arcapta Neohaler/Onbrez Breezhaler
        • Seebri Breezhaler
        • Theophylline
        • Flutiform
        • TABLE 65 SKYEPHARMA: PRODUCTS
        • TABLE 66 PARTNER NETWORK
        • Fluticasone/Salmeterol
        • TABLE 67 TOP SELLING INHALERS, 2010 ($ MILLIONS)
        • Tiotropium Bromide
      • Other Drugs
    • MAJOR PLAYERS
      • GlaxoSmithKline
      • TABLE 68 TOP SELLING DRUGS, 2010 ($ MILLIONS/+/- %)
    • CONCLUSION
      • Dry Powder Inhalation: A Promising Technology
      • TABLE 69 GROWTH AREAS FOR INHALERS
      • Generics for Advair: Teva
      • Nebulizers: Displaying Promising Growth
      • TABLE 70 GLOBAL RESPIRATORY DEVICE MARKET, THROUGH 2018 ($ MILLIONS)
      • FIGURE 13 GLOBAL RESPIRATORY DEVICE MARKET, 2011-2018 ($ MILLIONS)
      • TABLE 71 U.S. RESPIRATORY DEVICE MARKET, THROUGH 2018 ($ MILLIONS)
      • FIGURE 14 U.S. RESPIRATORY DEVICES MARKET, 2011-2018 ($ MILLIONS)
      • TABLE 72 GLOBAL MARKET FOR NEBULIZERS, THROUGH 2018 ($ MILLIONS)
      • FIGURE 15 GLOBAL MARKET FOR NEBULIZERS, 2011-2018 ($ MILLIONS)
      • Nebulizers on the Market

CHAPTER 7 GLOBAL MARKET TRENDS

  • GLOBAL TRENDS AND INHALER MARKET
    • ASIA
      • China
      • India
      • Iran
      • Regulatory Changes-Pulmonary Drug Delivery Hurdles
      • Increased Research and Development Efforts
      • Aerosol Delivery Market
      • Distribution Channels
    • GROWTH AND NEW DEVELOPMENTS
      • Pulmonary Disease Drug Market
      • Market Trends in Asia
      • Challenges and Future Development
      • Market Segmentation
      • Patient Involvement
      • Pulmonary Insulin
      • Exubera
      • Afrezza
    • INHALED SMALL MOLECULE THERAPEUTICS
    • TABLE 37 INHALED STEROID MEDICATIONS
    • SELECTED PROFILES OF DRUGS ON THE MARKET
      • Dulera
      • Arcapta (Indacaterol Maleate Inhalation Powder)
      • Daliresp 169

CHAPTER 8 KEY COMPANIES

  • KEY COMPANIES
  • KEY DEVELOPMENTS
  • SOME KEY COMPANIES AND DESCRIPTIONS
    • 3M
    • ADAMIS PHARMACEUTICALS CORP.
    • AKELA PHARMA INC (CANADA)
    • ALEXZA PHARMACEUTICALS
    • ALKERMES
    • ALPHARX INC.
    • AOP ORPHAN PHARMACEUTICALS
    • APT PHARMACEUTICALS INC.
    • APTAR PHARMA
    • ARADIGM CORP. (USA)
    • ASTRAZENECA PLC (U.K.)
    • AVANIR PHARMACEUTICALS
    • AXENTIS PHARMA
    • BOEHRINGER INGELHEIM
    • TABLE 74 COPD PRODUCTS
    • CIPLA
    • TABLE 75 RANGE OF DRY POWDER INHALER DEVICES
    • CONSORT MEDICAL PLC (UK)
    • DAIICHI SANKYO
    • DEY L.P. (USA)
    • GILEAD SCIENCES
    • GLAXOSMITHKLINE PLC (UK)
    • GRACEWAY PHARMACEUTICALS, LLC (USA)
    • HOVIONE
    • INSPIRE PHARMACEUTICALS INC.
    • MANNKIND
    • MAP PHARMACEUTICALS
    • MERCK & CO.
    • MICRODOSE THERAPEUTX
    • MPEX PHARMACEUTICALS
    • NEKTAR THERAPEUTICS
    • NEXT SAFETY
    • NOVARTIS INTERNATIONAL AG
    • OPTINOSE
    • ORIEL THERAPEUTICS INC.
    • PEARL THERAPEUTICS
    • PFIZER
    • PHARMAXIS
    • PULMATRIX
    • RESPIRICS
    • SAVARA
    • SKYEPHARMA PLC (UK)
    • SUNOVION PHARMACEUTICALS INC.
    • SYNAIRGEN RESEARCH LTD
    • TEVA NORTH AMERICA
    • THERAVANCE
    • UNITED THERAPEUTICS
    • VECTURA GROUP PLC (UK)

CHAPTER 9 KEY DEVELOPMENTS AND COLLABORATIONS

  • HISTORICAL FACTS
  • COMPANIES: DEVELOPMENTS OR INNOVATIVE PRODUCTS
    • ADAMIS PHARMACEUTICALS
    • MICRODOSE THERAPEUTX
    • THERAVANCE AND GLAXOSMITHKLINE
      • Theravance
      • GlaxoSmithKline
  • MYLAN ANNOUNCES ACQUISITION OF RIGHTS TO NOVEL LAMA RESPIRATORY COMPOUND FROM PFIZER
  • GSK'S INCRUSE
    • BOEHRINGER INGELHEIM (BI)
      • Civitas Therapeutics
    • PULMATRIX
    • MANNKIND'S INHALED INSULIN DRUG, AFREZZA
    • NOVARTIS
    • PEARL THERAPEUTICS
    • BAYER SCHERING PHARMA AG, GERMANY
    • DR. REDDY'S LABORATORIES
    • SUN PHARMA
    • SANDOZ
    • TEVA

CHAPTER 10 PATENT ANALYSIS

  • PATENT LANDSCAPE AND EFFECT ON SPENDING
  • TABLE 76 COPD KEY FACTS AND CHALLENGES
  • LATEST NEWS
    • ASTRAZENECA
  • REGULATORY ISSUES
    • NEW PATENT FILINGS
    • COMPETITIVE LANDSCAPE
    • TABLE 77 AREAS FOR DRUG DELIVERY IMPROVEMENTS
    • KEY PATENTS
      • Advair and Patent Issues
      • TABLE 78 PULMONARY DRUG DELIVERY TECHNOLOGIES AND KEY PATENTS
      • Proventil HFA
    • KEY FACTS
  • CONCLUSION

CHAPTER 11 REFERENCES

LIST OF TABLES

  • SUMMARY TABLE GLOBAL MARKET FOR PULMONARY DRUG DELIVERY TECHNOLOGIES, THROUGH 2018 ($ MILLIONS)
  • TABLE 1 COMMONLY USED INHALED DRUGS
  • TABLE 2 KEY FACTS
  • TABLE 3 ADVANTAGES AND DISADVANTAGES OF MDIS
  • TABLE 4 ALTERNATIVE TO CFC MDIS
  • TABLE 5 MDIS PHASE-OUT DATES: UNITED STATES
  • TABLE 6 COMMON DPI DEVICES
  • TABLE 7 DPI: ADVANTAGES AND DISADVANTAGES
  • TABLE 8 ADVANTAGES AND DISADVANTAGES OF NEBULIZERS
  • TABLE 9 INHALER DEVICES AND CHARACTERISTICS
  • TABLE 10 DOSAGE FORMS-INHALERS
  • TABLE 11 METERED DOSE INHALERS
  • TABLE 12 DRY POWDER INHALERS
  • TABLE 13 COMMON COPD INHALERS
  • TABLE 14 ASTHMA AND BIOMARKERS
  • TABLE 15 INHALED STEROIDS (ASTHMA INHALERS)
  • TABLE 16 SYSTEMIC STEROIDS FOR ASTHMA TREATMENT
  • TABLE 17 COPD AND LUNG DAMAGE
  • TABLE 18 COMMON COPD INHALERS ON THE MARKET
  • TABLE 19 COPD DRUGS ON THE MARKET
  • TABLE 20 INHALED DRUGS AND MARKET OPPORTUNITIES: CURRENT MARKET FOR INHALED DRUGS, 2010 (% MARKET SHARE)
  • TABLE 21 INHALER DEVICES
  • TABLE 22 DRUGS AND THERAPEUTIC AGENTS ADMINISTERED BY INHALATION
  • TABLE 23 BRAND NAME METERED DOSE INHALERS (CORTICOSTEROIDS)
  • TABLE 24 BRAND NAME METERED DOSE INHALERS (BRONCHODILATORS)
  • TABLE 25 LIST OF INHALERS FOR ASTHMA AND COPD WITHOUT CFCS
  • TABLE 26 LIST OF METERED DOSE INHALERS AND INGREDIENTS
  • TABLE 27 THE SEVEN CFC INHALERS
  • TABLE 28 TYPES OF DPI DEVICES
  • TABLE 29 DPIS CURRENTLY ON THE MARKET
  • TABLE 30 TYPES OF DRY POWDER INHALERS (DPI)
  • TABLE 31 NEBULIZERS AND DRUGS
  • TABLE 32 NEBULIZERS: ADVANTAGES AND DISADVANTAGES
  • TABLE 33 VIBRATING MESH NEBULIZERS
  • TABLE 34 THERAPEUTIC AGENTS ADMINISTERED BY INHALATION
  • TABLE 35 SHORT-ACTING BRONCHODILATOR INHALERS
  • TABLE 36 LONG-ACTING BRONCHODILATOR INHALERS
  • TABLE 37 INHALED STEROID MEDICATIONS
  • TABLE 38 COMBINATION INHALERS
  • TABLE 39 ASTHMA AND CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MARKET AND FORECAST, 2013 AND 2018 ($ MILLIONS)
  • TABLE 40 GLOBAL PHARMACEUTICAL SALES AND FORECAST, THROUGH 2018 ($ BILLIONS)
  • TABLE 41 TOTAL UNAUDITED AND AUDITED GLOBAL PHARMACEUTICAL MARKET BY REGION, THROUGH 2017 ($ BILLIONS)
  • TABLE 42 TOP 20 PHARMACEUTICAL COMPANIES, 2012 ($ MILLIONS)
  • TABLE 43 TWELVE LARGEST PHARMACEUTICAL COMPANIES, 2010 ($ MILLIONS)
  • TABLE 44 KEY PLAYERS: DRUG DELIVERY TECHNOLOGIES MARKET
  • TABLE 45 TOTAL GLOBAL DRUG DELIVERY TECHNOLOGIES MARKET, THROUGH 2018 ($ MILLIONS)
  • TABLE 46 GLOBAL DRUG DELIVERY TECHNOLOGIES MARKET, THROUGH 2018 ($ MILLIONS)
  • TABLE 47 GLOBAL ORAL DRUG DELIVERY TECHNOLOGIES MARKET, THROUGH 2018 ($ MILLIONS)
  • TABLE 48 GLOBAL IMPLANTABLE/INJECTABLE DRUG DELIVERY MARKET, THROUGH 2018 ($ MILLIONS)
  • TABLE 49 GLOBAL TRANSDERMAL DRUG DELIVERY TECHNOLOGIES MARKET, THROUGH 2018 ($ MILLIONS)
  • TABLE 50 U.S. DRUG DELIVERY TECHNOLOGIES MARKET AND FORECAST, THROUGH 2018 ($ MILLIONS)
  • TABLE 51 TOP ASTHMA AND COPD DRUGS
  • TABLE 52 GLOBAL PULMONARY DELIVERY TECHNOLOGIES MARKET, THROUGH 2018 ($ MILLIONS)
  • TABLE 53 LEADING PULMONARY DRUG DELIVERY PLAYERS
  • TABLE 54 PULMONARY DELIVERY TECHNOLOGIES MARKET IN THE U.S. AND EUROPE, THROUGH 2018 ($ MILLIONS)
  • TABLE 55 WORLDWIDE MARKET FOR TOP INHALED DRUGS: SALES AND FORECAST 2012-2013 ($ MILLIONS)
  • TABLE 56 UNITED STATES: TOP ASTHMA DRUGS SALES, 2012 AND 2013 ($ MILLIONS)
  • TABLE 57 MARKET FOR MDI TECHNOLOGIES, THROUGH 2018 ($ MILLIONS)
  • TABLE 58 DPI DEVICES
  • TABLE 59 MARKET FOR DPI TECHNOLOGIES, THROUGH 2018 ($ MILLIONS)
  • TABLE 60 TYPES OF INHALER UNITS SOLD WORLDWIDE, 2007 (%)
  • TABLE 61 UNITED STATES: TOP ASTHMA DRUGS PRESCRIPTIONS, 2012 ($ MILLIONS)
  • TABLE 62 NEW PRODUCTS IN THE RESPIRATORY DRUG MARKET, 2013
  • TABLE 63 ADVAIR SALES AND FORECAST, 2011-2015 ($ MILLIONS)
  • TABLE 64 GLAXOSMITHEKLINE: RESPIRATORY DRUGS PHARMACEUTICALS-THREE MONTHS ENDED JUNE 30, 2013 ($ MILLIONS)
  • TABLE 65 SKYEPHARMA: PRODUCTS
  • TABLE 66 PARTNER NETWORK
  • TABLE 67 TOP SELLING INHALERS, 2010 ($ MILLIONS)
  • TABLE 68 TOP SELLING DRUGS, 2010 ($ MILLIONS/+/- %)
  • TABLE 69 GROWTH AREAS FOR INHALERS
  • TABLE 70 GLOBAL RESPIRATORY DEVICE MARKET, THROUGH 2018 ($ MILLIONS)
  • TABLE 71 U.S. RESPIRATORY DEVICE MARKET, THROUGH 2018 ($ MILLIONS)
  • TABLE 72 GLOBAL MARKET FOR NEBULIZERS, THROUGH 2018 ($ MILLIONS)
  • TABLE 37 INHALED STEROID MEDICATIONS
  • TABLE 74 COPD PRODUCTS
  • TABLE 75 RANGE OF DRY POWDER INHALER DEVICES
  • TABLE 76 COPD KEY FACTS AND CHALLENGES
  • TABLE 77 AREAS FOR DRUG DELIVERY IMPROVEMENTS
  • TABLE 78 PULMONARY DRUG DELIVERY TECHNOLOGIES AND KEY PATENTS 13

LIST OF FIGURES

  • SUMMARY FIGURE GLOBAL MARKET FOR PULMONARY DRUG DELIVERY TECHNOLOGIES, 2011-2018 ($ MILLIONS)
  • FIGURE 1 ASTHMA AND CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MARKET AND FORECAST, 2013 AND 2018 ($ MILLIONS)
  • FIGURE 2 GLOBAL PHARMACEUTICAL SALES AND FORECAST, 2011-2018 ($ BILLIONS)
  • FIGURE 3 TOTAL GLOBAL DRUG DELIVERY TECHNOLOGIES MARKET, 2011-2018 ($ MILLIONS)
  • FIGURE 4 GLOBAL DRUG DELIVERY TECHNOLOGIES MARKET, 2011-2018 ($ MILLIONS)
  • FIGURE 5 GLOBAL ORAL DRUG DELIVERY TECHNOLOGIES MARKET, 2012-2018 ($ MILLIONS)
  • FIGURE 6 GLOBAL IMPLANTABLE/INJECTABLE DRUG DELIVERY MARKET, 2011-2018 ($ MILLIONS)
  • FIGURE 7 GLOBAL TRANSDERMAL DRUG DELIVERY TECHNOLOGIES MARKET, 2011-2018 ($ MILLIONS)
  • FIGURE 8 U.S. DRUG DELIVERY TECHNOLOGIES MARKET, 2011-2018 ($ MILLIONS)
  • FIGURE 9 GLOBAL PULMONARY DELIVERY TECHNOLOGIES MARKET, 2011-2018 ($ MILLIONS)
  • FIGURE 10 PULMONARY DRUG DELIVERY TECHNOLOGIES MARKET IN THE U.S. AND EUROPE, 2011-2018 ($ MILLIONS)
  • FIGURE 11 MARKET FOR MDI TECHNOLOGIES, 2011-2018 ($ MILLIONS)
  • FIGURE 12 MARKET FOR DPI TECHNOLOGIES, 2011-2018 ($ MILLIONS)
  • FIGURE 13 GLOBAL RESPIRATORY DEVICE MARKET, 2011-2018 ($ MILLIONS)
  • FIGURE 14 U.S. RESPIRATORY DEVICES MARKET, 2011-2018 ($ MILLIONS)
  • FIGURE 15 GLOBAL MARKET FOR NEBULIZERS, 2011-2018 ($ MILLIONS)
Back to Top